Form 4: Puma Biotechnology Insider Sells Shares

Alan H. Auerbach, Director, President and CEO of Puma Biotechnology, Inc., reported a transaction involving the sale of common stock.

Summary

• Alan H. Auerbach, who holds the positions of Director, President, and CEO at Puma Biotechnology, Inc., has reported a transaction.
• The transaction involved the sale of 44,058 shares of common stock.
• The sale occurred on July 6, 2026, with a transaction code 'S' indicating a sale.
• The price per share for this transaction was $8.263.
• Following this transaction, Mr. Auerbach beneficially owns 7,261,671 shares of common stock, held directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the pre-planned nature via a 10b5-1(c) plan mitigates immediate concern.

Negatives

• Insider selling of a significant number of shares by a key executive can sometimes be perceived negatively by the market.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Management Comments

• The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The sale of shares by a CEO can be interpreted in various ways, but the mention of a Rule 10b5-1(c) plan suggests it was pre-planned and may not necessarily reflect a negative view of the company's future prospects.

Stakeholder Impact

• Shareholders may view the sale of a significant number of shares by the CEO with caution, although the pre-planned nature of the sale under a 10b5-1(c) plan may temper concerns.

Key Dates

Keywords

Puma Biotechnology, PBYI, Insider Trading, Form 4, Stock Sale, Beneficial Ownership, Alan H. Auerbach